Mirae Asset Global ETFs Holdings
ACAD icon

Mirae Asset Global ETFs Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.11M Sell
83,493
-2,771
-3% -$61K ﹤0.01% 1215
2026
Q1 		$1.9M Buy
86,264
+4,657
+6% +$111K ﹤0.01% 1186
2025
Q4 		$2.18M Buy
81,607
+1,866
+2% +$44.6K ﹤0.01% 1115
2025
Q3 		$1.7M Sell
79,741
-5,433
-6% -$128K ﹤0.01% 1215
2025
Q2 		$1.84M Sell
85,174
-4,778
-5% -$88.8K ﹤0.01% 1138
2025
Q1 		$1.5M Buy
89,952
+6,303
+8% +$115K ﹤0.01% 1281
2024
Q4 		$1.53M Sell
83,649
-3,256
-4% -$52.6K ﹤0.01% 1316
2024
Q3 		$1.34M Buy
86,905
+3,768
+5% +$62.9K ﹤0.01% 1371
2024
Q2 		$1.35M Buy
+83,137
New +$1.34M ﹤0.01% 1286

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's ACAD Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Acadia Pharmaceuticals (ACAD) stake by 3.2% in Q2 2026, selling an estimated $61K and leaving 83,493 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

Mirae Asset Global ETFs Holdings first reported a position in ACAD in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.18M in Q4 2025. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 83,493 shares of Acadia Pharmaceuticals worth $2.11M as of Q2 2026.
  • Mirae Asset Global ETFs Holdings sold 2,771 Acadia Pharmaceuticals shares in Q2 2026, an estimated $61K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1215 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Acadia Pharmaceuticals position peaked at $2.18M in Q4 2025.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.